Compare Lemonade Inc (LMND) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Merck & Co., Inc. — how do they compare? Lemonade Inc trades at $46.46 (market cap $3.63B), while Merck & Co., Inc. trades at $145.6 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 96.8× Lemonade Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Merck & Co., Inc. for 98 Days on average.
| LMND | MRK | |
|---|---|---|
Market Cap | $3.63B | $351.28B |
Volume | 1,544,794 | 7,969,665 |
Sector | Financials | Health |
52-Week High | $96.57 | $156.43 |
52-Week Low | $43.91 | $82.49 |
Typical Hold Time | 27 Days | 98 Days |
Enterprise Value | $3.49B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $46.91, up 0.17% on the day, with a bearish technical signal driven by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $738 million, and net losses narrowing to -$166 million. Recent news highlights expansion into new states and AI-driven efficiency gains, with management targeting EBITDA profitability by late 2026.
The outlook is mixed: growth and margin improvement offer upside, but persistent losses and high valuation multiples pose risks. Analysts are divided with a consensus price target of $67, suggesting potential upside if profitability targets are met. Key risks include execution on profitability and competitive pressures in the insurtech space.
Merck (MRK) trades at $142.40, down 0.28% on the day, with a bearish technical signal and key support at $140. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.14. Revenue grew to $65.01B in 2025, and net income reached $18.25B, though the P/E ratio is elevated at 113.9. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook for MRK is mixed, with solid fundamentals and analyst optimism countered by high valuation and bearish technicals. The consensus price target of $158.78 suggests upside potential, but investors face risks from competitive pressures and integration challenges from recent M&A activity. Earnings growth and pipeline developments remain key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
